Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections

Abstract

Health professionals and the public need to understand the natural history of human papillomavirus (HPV) infections of the cervix to best use the information provided by new molecular screening tests. We investigated outcomes of 800 carcinogenic HPV infections detected in 599 women at enrollment into a population-based cohort (Guanacaste, Costa Rica). For individual infections, we calculated cumulative proportions of three outcomes (viral clearance, persistence without cervical intraepithelial neoplasia grade 2 or worse [CIN2+], or persistence with new diagnosis of CIN2+) at successive 6-month time points for the first 30 months of follow-up. Cervical specimens were tested for carcinogenic HPV genotypes using an L1 degenerate-primer polymerase chain reaction method. Infections typically cleared rapidly, with 67% (95% confidence interval [CI] = 63% to 70%) clearing by 12 months. However, among infections that persisted at least 12 months, the risk of CIN2+ diagnosis by 30 months was 21% (95% CI = 15% to 28%). The risk of CIN2+ diagnosis was highest among women younger than 30 years with HPV-16 infections that persisted for at least 12 months (53%; 95% CI = 29% to 76%). These findings suggest that the medical community should emphasize persistence of cervical HPV infection, not single-time detection of HPV, in management strategies and health messages.

Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study

“…Indira Mendiola-Pastrana, MSc, (1) Samantha E Rudolph, MS, (5,6) Leith León-Maldonado, DPH, (1,7) Rubí Hernández, MSc,…”

GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial

“…Although our virology results indicated that GTL001 þ imiquimod might enhance HPV clearance, the results may be due to or masked by spontaneous clearance, which can occur within 1 year in as many as half of HPV16-and HPV18-infected women (37). Furthermore, this phase I trial was not designed to detect significant differences in viral clearance, and we cannot exclude the possibility of transient HPV carriage following a recent sexual exposure.…”

Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology

“…Because of maximal exposure but minimal acquired immunity, HPV prevalence is high in young women (Bosch et al, 2008;McKenna and McMenamin, 2014). However, most young women have an effective immune response to clear the acute infection within a short time (Rodriguez et al, 2008). Considering the high spontaneous regression rate among this age group, HPV testing is not recommended (Davey et al, 2014).…”